CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s Second Quarter 2023 Financial Results and Business Update Conference Call.
Cymabay Therapeutics Inc. (CBAY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 10,300,000 | $112,785,000 | 1.53% | |
| 2. | Octagon Capital Advisors Ting Jia | 4,570,918 | $50,051,552 | 6.96% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 4,401,292 | $48,194,147 | +1% | 0.1% |
| 4. | Cormorant Asset Management Bihua Chen | 3,800,000 | $41,610,000 | +199% | 2.33% |
| 5. | Perceptive Advisors Joseph Edelman | 3,733,255 | $40,879,142 | -5% | 1.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.95 | 51,301 | Officer, Director | 171,301 | 2022-06-06 | Filing | |
| $3.04 | 20,000 | Officer | 20,000 | 2022-01-19 | Filing | |
| $4.30 | 5,000 | Officer, Director | 120,000 | 2019-10-10 | Filing | |
| $5.55 | 3,100 | Officer, Director | 115,000 | 2019-09-23 | Filing | |
| $5.50 | 1,900 | Officer, Director | 111,900 | 2019-09-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.68 | 15,921 | Director | 90,000 | 2023-09-29 | Filing | |
| $16.22 | 21,746 | Officer | 15,000 | 2023-09-18 | Filing | |
| $16.87 | 0 | Officer | 0 | 2023-09-15 | Filing | |
| $16.87 | 0 | Officer | 0 | 2023-09-15 | Filing | |
| $16.87 | 24,000 | Officer | 0 | 2023-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,746,587 | $84,849,183 | 0.05% | |
| 2. | 7,504,670 | $82,176,135 | 0% | |
| 3. | 5,148,880 | $56,380,236 | 0% | |
| 4. | 3,272,008 | $35,828,487 | 0.01% | |
| 5. | 2,500,000 | $27,375,000 | 2.81% |
News See All
5 Best Medical Stocks Under $10
In this piece, we will take a look at the five best medical stocks under $10.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q1 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to CymaBay’s First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
5 Best Biotech Stocks to Buy Under $20
Biohaven Ltd. (NYSE:BHVN) is an American company headquartered in New Haven, Connecticut.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript
Operator: Good day ladies and gentlemen and welcome to CymaBay's Fourth Quarter and Full-Year 2022 Financial Results and Business Update Conference Call.
5 Best Biotech Stocks Under $10
In this article, we will look at the 5 best biotech stocks under $10.
10 Best Biotech Stocks Under $10
In this article, we will take a look at the 10 best Biotech stocks under $10.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Ken Griffin, Clint Carlson, Renaissance Technologies, EcoR1 Capital, Lodbrok Capital, Phillips 66 Partners LP (PSXP), and More
New York - US regulators have rejected former White House communications director Anthony Scaramucci's hedge fund's filing to list a bitcoin exchange-traded fund.
10 Micro-Cap Stocks to Buy According to Hedge Funds
In this article, we will discuss 10 micro-cap stocks to buy according to hedge funds.
Were Hedge Funds Right About CymaBay Therapeutics Inc (CBAY)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Billionaire Hedge Funds
